Shanghai MicroPort Endovascular MedTech (688016) Fundamentals 2026 — P/E 18.9x, Revenue Analysis | SniperIQ
Shanghai MicroPort Endovascular MedTech (688016) is a CN-listed Healthcare company in Medical - Devices with a market capitalization of ¥11.1B, trading at ¥91.84 on the SHH. This SniperIQ fundamentals page covers Shanghai MicroPort Endovascular MedTech's valuation (P/E 18.9x, P/B 2.6x), profitability (net margin 42.4%), revenue (¥1.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shanghai MicroPort Endovascular MedTech's market cap?
Shanghai MicroPort Endovascular MedTech (688016) has a market capitalization of approximately ¥11.1B, trading at ¥91.84 on the SHH. Market cap moves with the live share price.
What is Shanghai MicroPort Endovascular MedTech's P/E ratio?
Shanghai MicroPort Endovascular MedTech's trailing twelve-month P/E ratio is 18.9x, with a price-to-book (P/B) of 2.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shanghai MicroPort Endovascular MedTech?
Shanghai MicroPort Endovascular MedTech runs a net profit margin of 42.4%, a gross margin of 71.2%, and an operating margin of 48.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shanghai MicroPort Endovascular MedTech generate?
Shanghai MicroPort Endovascular MedTech reported revenue of ¥1.3B for fiscal year 2025, with net income of ¥563M and earnings per share (EPS) of 4.65. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shanghai MicroPort Endovascular MedTech pay a dividend?
Shanghai MicroPort Endovascular MedTech offers a trailing dividend yield of about 2.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shanghai MicroPort Endovascular MedTech financially healthy?
Shanghai MicroPort Endovascular MedTech carries a debt-to-equity ratio of 0.00x and a current ratio of 6.94x, with a market beta of 0.20. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shanghai MicroPort Endovascular MedTech a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shanghai MicroPort Endovascular MedTech (688016) the key facts are: market cap ¥11.1B, P/E 18.9x, revenue ¥1.3B, 52-week range 83.33-124.3. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shanghai MicroPort Endovascular MedTech's full fundamentals live
Get Shanghai MicroPort Endovascular MedTech's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.